KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Astrazeneca (AZN) Invested Capital (2016 - 2025)

Astrazeneca (AZN) has 3 years of Invested Capital data on record, last reported at $78.3 billion in Q4 2025.

  • For Q4 2025, Invested Capital rose 10.21% year-over-year to $78.3 billion; the TTM value through Dec 2025 reached $78.3 billion, up 10.21%, while the annual FY2025 figure was $78.3 billion, 10.21% up from the prior year.
  • Invested Capital reached $78.3 billion in Q4 2025 per AZN's latest filing, up from $71.1 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $78.3 billion in Q4 2025 and bottomed at $67.8 billion in Q4 2023.
  • Average Invested Capital over 3 years is $72.4 billion, with a median of $71.1 billion recorded in 2024.
  • Peak YoY movement for Invested Capital: grew 4.86% in 2024, then rose 10.21% in 2025.
  • A 3-year view of Invested Capital shows it stood at $67.8 billion in 2023, then rose by 4.86% to $71.1 billion in 2024, then rose by 10.21% to $78.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $78.3 billion in Q4 2025, $71.1 billion in Q4 2024, and $67.8 billion in Q4 2023.